PART I . General Provectus Biopharmaceuticals, Inc., a Delaware corporation (together with its subsidiaries, Provectus or the Company), is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases. Our drug product candidates are based on bioactive, synthetic, small molecule rose bengal sodium (RBS), which is a member of a class of molecules called halogenated xanthenes (HXs). The Companys proprietary, patented, pharmaceutical-grade RBS is the active pharma...
Q2 FY2026 — expected 2026-08-17
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-26 | 2025-12-31 | 0001493152-26-012726 | EDGAR | 42K words |
| 2025-03-28 | 2024-12-31 | 0001641172-25-000993 | EDGAR | — |
| 2024-03-28 | 2023-12-31 | 0001493152-24-011699 | EDGAR | — |
| 2023-03-30 | 2022-12-31 | 0001493152-23-009563 | EDGAR | — |
| 2022-03-29 | 2021-12-31 | 0001493152-22-008016 | EDGAR | — |
| 2021-03-02 | 2020-12-31 | 0001493152-21-005194 | EDGAR | — |
| 2020-03-05 | 2019-12-31 | 0001493152-20-003433 | EDGAR | — |
| 2019-03-07 | 2018-12-31 | 0001493152-19-002987 | EDGAR | — |
| 2018-03-23 | 2017-12-31 | 0001493152-18-003771 | EDGAR | — |
| 2017-03-31 | 2016-12-31 | 0001193125-17-106543 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-13 | 2025-09-30 | 0001493152-25-022229 | EDGAR | 24K words |
| 2025-08-14 | 2025-06-30 | 0001641172-25-023864 | EDGAR | — |
| 2025-05-14 | 2025-03-31 | 0001641172-25-010273 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001493152-24-044720 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0001493152-24-031524 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0001493152-24-019184 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0001493152-23-040856 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0001493152-23-028230 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0001493152-23-016356 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0001493152-22-031108 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001493152-22-022049 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0001493152-22-012970 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-02 | 0001493152-26-004730 | EDGAR | 1K words |
| 2025-06-20 | 0001641172-25-015695 | EDGAR | — |
| 2025-06-18 | 0001641172-25-015520 | EDGAR | — |
| 2025-04-16 | 0001641172-25-004995 | EDGAR | — |
| 2025-01-22 | 0001493152-25-003193 | EDGAR | — |
| 2024-12-26 | 0001493152-24-052029 | EDGAR | — |
| 2024-12-11 | 0001493152-24-049571 | EDGAR | — |
| 2024-12-05 | 0001493152-24-048734 | EDGAR | — |
| 2024-11-14 | 0001493152-24-045353 | EDGAR | — |
| 2024-08-19 | 0001493152-24-033053 | EDGAR | — |
410 total filings indexed. 378 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000315545 |
| Ticker | PVCT |
| Exchange | OTC |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report